Withholding interferon-alpha from patients with chronic myeloid leukaemia prior to bone marrow examination does not improve the chance of a successful cytogenetic analysis.
Anthony P
AP
Schwarer
Meaghan
M
Wall
Merrole
M
Cole-Sinclair
Lynda
L
Campbell
Jennifer
J
Muirhead
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001854:Bone Marrow Cells / Q000187:drug effects; D001856:Bone Marrow Examination / Q000379:methods; D020732:Cytogenetic Analysis / Q000379:methods*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics*; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins